Delly Ramadon is an associate professor in transdermal/intradermal drug delivery system and head of the Pharmaceutics and Pharmaceutical Technology Laboratory at the Faculty of Pharmacy, Universitas Indonesia. He obtained his PhD degree from the School of Pharmacy, Queen’s University Belfast, UK, in 2020. His research is focused on transdermal/intradermal drug delivery system using various kinds of enhancement strategies, including permeation enhancers, nanoparticles, nanovesicles, and polymeric microneedles. His research has been supported by research grants from Universitas Indonesia; the Ministry of Higher Education, Science, and Technology, Republic of Indonesia; the National Research and Innovation Agency (BRIN) of Indonesia; and overseas pharmaceutical companies. In 2022, he has served as a Postdoctoral Research Fellow at Daewoong Pharmaceuticals, South Korea. He was also invited as a Visiting Scholar in the Global Excellence in Pharmacy program at Ulster University in 2024 funded by the International Science Partnerships Fund, Department for the Economy, Northern Ireland.

Zhang Jingyan is a third-year Ph.D. candidate at Zhejiang University's School of Pharmacy. Her doctoral research, conducted under the guidance of Professor Hu, focuses on the critical challenge of developing advanced drug delivery systems for the targeted treatment of glioblastoma multiforme (GBM), a highly aggressive and difficult-to-treat brain tumor. Ms. Zhang's work specifically investigates the design, synthesis, and evaluation of novel nanocarriers and targeting strategies aimed at enhancing the precision, efficacy, and safety of therapeutic agents delivered to brain tumor sites while overcoming biological barriers like the blood-brain barrier. Her research integrates principles from pharmaceutical sciences, nanotechnology, and molecular biology to address the urgent clinical need for more effective GBM therapies. She is actively engaged in characterizing these delivery platforms in vitro and in vivo, aiming to translate her findings towards improved therapeutic outcomes for brain cancer patients.

Dr. Roy has academic degrees from top NIRF ranked Universities. PhD from Department of Pharmaceutical Technology, Jadavpur University, Kolkata (NIRF 4) in 2014. B. Pharm from M. S. Ramaiah College of Pharmacy-Bangalore (NIRF 15) & M. Tech (Medicinal Chemistry) from VIT-Vellore (NIRF-9). He's the recipient of 3 prestigious central govt. fellowships namely, UGC-JRF in Engineering (Pharmacy), and UGC-Major Research Project Fellow during PhD tenure in 2012, as well as, UGC-RUSA Post Doctoral Fellowship in 2019. His Post Doctoral Research (2016-2018) was from University of Missouri, Kansas City (UMKC), USA and University of the Pacific (UoP), California, USA. Research work in UMKC focused on “Designing siRNA loaded fluorescent nanoparticles engineered with dual peptides for brain tumor targeting”. He is the 1st author of several American Chemical Society publications and the member and reviewer of American Chemical Society, Washington.

Dr. Priyadarshini Mohapatra is a nanomedicine researcher with expertise in biomaterials, drug delivery, and targeted cancer therapy. She completed her Ph.D. in Nanomedicne/Biomedical Science at Vellore Institute of Technology under ICMR funding, focusing on core-shell nanoformulations targeting the Wnt/β-catenin pathway in liver cancer. She has served as a Senior Research Fellow at ICMR and held a postdoctoral position at Alliance University, Bengaluru. With over seven peer-reviewed publications and presentations at six national and international conferences, she has also received the Trialect Fellowship and contributed as a reviewer for reputed journals.

Ms. Ge is a Master's candidate in Pharmaceutics at Nanjing University of Chinese Medicine, under the supervision of Professor Yiwei Wang. Her research focuses on innovative drug delivery systems for reproductive health, dedicated to developing patient-centric long-acting contraceptive technologies. Her core achievement is an injectable biodegradable hydrogel platform. Through precise control of polymer networks, it achieves >90% drug encapsulation efficiency and maintains stable plasma drug concentrations for over 20 days in rodent models. She innovatively combines material synthesis with in vitro permeability evaluation to significantly enhance the bioavailability of hormonal contraceptives while reducing their side effects. This research bridges modern pharmaceutical engineering with global family planning needs, providing a breakthrough solution for long-acting contraceptive systems. Her presentation will detail the platform's design principles and preclinical validation data, demonstrating its "low-frequency dosing" technological advantage.

He graduated from the Faculty of Pharmaceutical Sciences at Tokyo University of Science in 2024 and entered the Maser course at the Graduate School of Pharmaceutical Sciences at the same university in the same year. He is currently a second-year student in the Laboratory of Biopharmaceutics. He has received several awards, including the Student Oral Presentation Awards at the 144th (2024) and 145th (2025) Annual Meeting of the Pharmaceutical Society of Japan, as well as the Best Presenter Award at the 40th Annual Meeting of the Academy of Pharmaceutical Science and Technology, Japan (2025).

Ayca Altay Benetti is recognized for her expertise in pharmacokinetics and targeted drug delivery formulation. In 2016, she led a regional project in Emilia-Romagna (Italy), collaborating with Chiesi, IMA SpA, and Bormioli Pharma to develop a pulmonary cystic fibrosis treatment combining small molecules and biotech APIs, successfully brought to market. During her PhD at the University of Parma, she consulted for major pharmaceutical companies (GSK, Lonza, Evotec, Angelini, Menarini, Ceva, Chiesi), supporting pharmacokinetic studies and formulation scale-ups. In 2022, she joined the National University of Singapore as a research fellow under Prof. Giorgia Pastorin. She also founded PronioBioTech, a startup in transdermal drug delivery for arthritis, following her graduation from the NUS GRIP 10 innovation program. With over 20 peer-reviewed publications and numerous international presentations. Her journey reflects a commitment to bridging academia and industry in advancing pharmaceutical innovation.